Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Rimonabant, Metformin, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: COVID, Coronavirus, COVID-19
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Rett Syndrome
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas

Conditions: Ileus Postoperative, Postoperative Nausea and Vomiting
Interventions: gastric point of care ultrasound; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small Cell Lung Cancer
Interventions: ASA404, Placebo, docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 88
States / cities: Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more

Conditions: Cushing Syndrome
Interventions: Relacorilant, Placebo; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more

Conditions: SARS-CoV2 Infection, COVID-19
Interventions: IMM-BCP-01, Placebo; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Long Beach, California • Miami Lakes, Florida • New York, New York

Conditions: Autoimmune Diseases, Multiple Sclerosis
Interventions: LPX-TI641; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Baricitinib, cDMARD; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 32
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Motion Sickness
Interventions: scopolamine HBr, Transdermal Scopolamine; Drug
Lead sponsor: Repurposed Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Autism Spectrum Disorder
Interventions: Oral cannabidiol 100mg/mL, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 17 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atopic Dermatitis
Interventions: TRIV-509, Placebo; Drug
Lead sponsor: Triveni Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Fountain Valley, California • San Diego, California • Miami, Florida + 6 more

Conditions: Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions: Fluticasone propionate/salmeterol, Fluticasone Propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 50
States / cities: Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more

Conditions: Congestive Heart Failure
Interventions: MCC-135, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 47 more

Conditions: Stress Urinary Incontinence
Interventions: AMDC-USR (iltamiocel), Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more

Conditions: Sarcoidosis, Pulmonary
Interventions: Atorvastatin, Placebo Oral Tablet; Drug · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dravet Syndrome
Interventions: zorevunersen, Sham Comparator; Drug · Other
Lead sponsor: Stoke Therapeutics, Inc; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more

Conditions: Methamphetamine-dependence
Interventions: Magnetic resonance imaging (MRI), Methamphetamine Hydrochloride Tablets, Placebo oral tablet; Behavioral · Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Drug Abuse
Interventions: Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: oGHVD
Interventions: d-MAPPS, Placebo, PI and Patient Masked; Biological · Other
Lead sponsor: Regenerative Ocular Immunobiologics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Beverly Hills, California • Huntington Beach, California • Palm Harbor, Florida + 2 more

Conditions: Breast Cancer
Interventions: Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 23
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more

Conditions: Cystic Fibrosis
Interventions: VX-809, VX-770, VX-809 placebo, VX-770 placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Postoperative Gastric Point of Care Ultrasound (G-POCUS) in Abdominal Surgery

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

IMM-BCP-01 in Mild to Moderate COVID-19

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

A Moderate to Severe Rheumatoid Arthritis Study

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr

A Study Evaluating TRIV-509 in Atopic Dermatitis

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Atorvastatin to Treat Pulmonary Sarcoidosis

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Effects of Genotype on Resting State Connectivity During Methamphetamine Administration

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects